Home › Stocks › Cipla vs Dr Reddy's

Cipla vs Dr Reddy's — which is better value?

The closest peer on US-generics exposure. This page sets the two side by side on their filed records, what each share price assumes, and what decides each one's value.

FairStocks Research
Updated 16 Nov 2026 · 3 min read
| NSE: CIPLA NSE: DRREDDY
On this page ▾
  1. Two businesses
  2. The records side by side
  3. What each price assumes
  4. What decides each value
  5. What could go wrong
  6. Which is better value?
  7. Related comparisons
  8. Questions
In 30 seconds

Today's prices ask more of Cipla than of Dr Reddy's.

At current prices, buyers of Cipla are assuming about 2% growth against 7% in its own record; for Dr Reddy's it is 0% against 13%. That shows which share needs more to go right — not which is cheaper. How far each trades from its estimated fair value is in the full valuations.

  • Valuation method: both on discounted cash flow.
  • Size: the two are worth roughly the same on the stock market.
  • Record: Dr Reddy's has grown revenue faster: Cipla compounded at about 8% a year (FY2018–FY2026) and Dr Reddy's at about 11% (FY2018–FY2026).
  • What to watch: complex us generics at Cipla; replacing revlimid at Dr Reddy's.
CiplaDr Reddy's
Price₹1,394₹1,378
Market cap₹1.13L Cr₹1.15L Cr
P/E38.941.1
P/B3.273.04
Fair value 🔒 sign in₹0,000₹0,000
Upside 🔒 sign in+00%+00%
Valued onDiscounted cash flowDiscounted cash flow
See both fair values, side by sideEvery step of each working, the scenarios and the reports Free during launch →

01Two businesses

CiplaCIPLA

Ninety years of affordable medicine

Cipla was founded in 1935 by Khwaja Abdul Hamied and became known worldwide for low-cost HIV medicines in the early 2000s. Today it is one of India's largest pharmaceutical companies, with strong positions in India, South Africa and the US.

Dr Reddy'sDRREDDY

A Hyderabad generics maker with a global footprint

Dr Reddy's Laboratories was founded in Hyderabad in 1984 by Dr K. Anji Reddy. It makes generic medicines for the US, India, Russia and other emerging markets, and active pharmaceutical ingredients that it sells to other drugmakers.

02The records side by side

Dr Reddy's has grown revenue faster: Cipla compounded at about 8% a year (FY2018–FY2026) and Dr Reddy's at about 11% (FY2018–FY2026). By revenue the two are of broadly similar size. Cipla kept 13.7% of revenue as net profit in FY2026; Dr Reddy's kept 12.3% of revenue as net profit in FY2026.

Dr Reddy's. The jump in margins from FY2023 and the fall in FY2026 profit largely track the limited-volume Revlimid generic in the US, which was never going to last.

Full ten-year tables and charts are on each company's page: Cipla · Dr Reddy's.

03What each price assumes

Work backwards from each share price and you can see what buyers are taking for granted — the rate each company must sustain to justify what it costs, against what its own record supports.

Price implies
2%
growth
Record supports
7%
growth
Price implies
0%
growth
Record supports
13%
growth

04What decides each one's value

  • Complex US genericsInhalers and other hard-to-make products face less competition than simple pills.
  • India branded businessSteady, cash-rich and growing with the domestic market.
  • Replacing RevlimidNew US launches and other markets need to fill the gap left by one very profitable product.
  • US generic pricingPrices for older generics keep falling, so the pipeline has to keep moving.

05What could go wrong

  • FDA complianceInspection problems at key plants have delayed launches before.
  • US price erosionGeneric prices fall as competitors enter.
  • FDA inspectionsAdverse findings at a plant can block US approvals and shipments.
  • Pipeline delaysLate approvals push out the launches that replace lost profit.

06Which is better value?

Cipla
Fair value per share
₹0,000
Upside
+00%
Dr Reddy's
Fair value per share
₹0,000
Upside
+00%

Sign in free to see which trades further below its worth

  • ✓Both fair values per share — each on the method that fits the business
  • ✓Every step of both workings — growth, margins and cost of capital, with sources
  • ✓Bull, base and bear cases — for each company
  • ✓Downloadable reports — the full write-up for each, yours to keep
Free during launch · unlimited valuations · no card required

08Questions people ask

Is Cipla or Dr Reddy's better value?

That turns on how far each share trades from its estimated fair value. Both figures, with every step of the working, are in the full valuations, free to view once you sign in. On the public numbers, Cipla trades at 38.9 times earnings and 3.27 times book value, and Dr Reddy's at 41.1 times earnings and 3.04 times book value — but multiples alone mislead when two businesses work differently, which is why each is valued on the method that fits it.

What is the difference between Cipla and Dr Reddy's?

Cipla was founded in 1935 by Khwaja Abdul Hamied and became known worldwide for low-cost HIV medicines in the early 2000s. Dr Reddy's Laboratories was founded in Hyderabad in 1984 by Dr K.

Are Cipla and Dr Reddy's valued the same way?

Yes — both on discounted cash flow, so their workings compare like for like.

What does today's price assume for Cipla and Dr Reddy's?

Worked backwards from the share price, Cipla needs about 2% growth and Dr Reddy's about 0% growth, against 7% and 13% in their own records.

About this comparison

Written by the FairStocks research team from both companies' filed accounts; figures refresh as new results are filed. Each company is valued on the method that fits it — see a fully worked example or the valuation guides. Educational research, not investment advice.

See both fair valuesUnlock free